여성형유방 환자에서 타목시펜 치료 효과
The effect of Tamoxifen on Patients with Gynecomastia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Gynecomastia is the most common cause of male breast enlargement and is a disease which can occur in men of all ages. The purpose of this study was to evaluate the effect of tamoxifen on size reduction of breast tissue in gynecomastia patients, regardless of age and symptoms. We also, aimed to investigate the advantages and disadvantages of tamoxifen compared to surgery and other medications. Methods: Twenty patients diagnosed with gynecomastia at the Breast and Thyroid Surgery Department, of Wonkwang University Hospital from January 2013 to February 2019 were included. All patients received tamoxifen 20 mg once a day or 10 mg twice a day; two months of treatment was planned, and medication was administered. The diameter and depth of the gynecomastia tissue were followed up with breast ultrasound before and after treatment. A survey of age, nationality, location, symptoms, duration of symptoms, previous history, and causes was also conducted. Results: Breast tissue size was measured by ultrasound when the gynecomastia patients first visited and after using tamoxifen. As a result, mean diameter decreased by 41.9%, mean thickness decreased by 41.0%, and estimated mean volume decreased by 74.3%, except for one patient with recurrence. No side effects of tamoxifen were found in this study. Conclusion: Since tamoxifen treatment has few side effects and recurrence is rarely reported at the time of discontinuation, it is a good primary treatment. But secondary treatment should be considered if there is no subsequent reaction. Surgical treatment may also be considered for gynecomastia patients with Tanner’s breast stage higher than 4, or who want an immediate reduction in breast size.
Abstract
Purpose: Gynecomastia is the most common cause of male breast enlargement and is a disease which can occur in men of all ages. The purpose of this study was to evaluate the effect of tamoxifen on size reduction of breast tissue in gynecomastia patients, regardless of age and symptoms. We also, aimed to investigate the advantages and disadvantages of tamoxifen compared to surgery and other medications. Methods: Twenty patients diagnosed with gynecomastia at the Breast and Thyroid Surgery Department, of Wonkwang University Hospital from January 2013 to February 2019 were included. All patients received tamoxifen 20 mg once a day or 10 mg twice a day; two months of treatment was planned, and medication was administered. The diameter and depth of the gynecomastia tissue were followed up with breast ultrasound before and after treatment. A survey of age, nationality, location, symptoms, duration of symptoms, previous history, and causes was also conducted. Results: Breast tissue size was measured by ultrasound when the gynecomastia patients first visited and after using tamoxifen. As a result, mean diameter decreased by 41.9%, mean thickness decreased by 41.0%, and estimated mean volume decreased by 74.3%, except for one patient with recurrence. No side effects of tamoxifen were found in this study. Conclusion: Since tamoxifen treatment has few side effects and recurrence is rarely reported at the time of discontinuation, it is a good primary treatment. But secondary treatment should be considered if there is no subsequent reaction. Surgical treatment may also be considered for gynecomastia patients with Tanner’s breast stage higher than 4, or who want an immediate reduction in breast size.
참고문헌 (27)
- Eberlein TJ, "Diseases of the breast", pp.46~50 (1996), Lippincott-Raven
- "The best Clinical Endocrinology source in the world"[URL]
- Choi KH, "Treatment of gynecomastia with tamoxifen", Surg Treat Res, 48, pp.741~744 (1995)
- Khan HN, "Management of physiological gynaecomastia with tamoxifen", Breast, 13, pp.61~65 (2004)
- Parker LN, "Treatment of gynecomastia with tamoxifen: a double-blind crossover study", Metabolism, 35, pp.705~708 (1986)
- Nuttall FQ, "Gynecomastia as a physical finding in normal men", J Clin Endocrinol Metab, 48, pp.338~340 (1979)
- Stang J, "Guidelines for adolescent nutrition services", pp.1~7 (2005), Center for Leadership, Education and Training in Maternal and Child Nutrition
- Braustein GD, "Gynecomastia", N Engl J Med, 328, pp.490~495 (1993)
- Wibowo E, "Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy", J Urol, 185, pp.17~23 (2011)
- Thompson DF, "Drug-induced gynecomastia", Pharmacotherapy, 13, pp.37~45 (1993)
- Caeiro JP, "Gynecomastia associated with indinavir therapy", Clin Infect Dis, 27, pp.1539~1540 (1998)
- Picolos MK, "Rosuvastatin-induced gynaecomastia", Clin Endocrinol (Oxf), 73, pp.421~422 (2010)
- Garcia Rodriguez LA, "Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs", BMJ, 308, pp.503~ (1994)
- Carrie A, "Andropause:symptom management for prostate cancer patients treated with hormonal ablation", Oncologist, 8, pp.474~487 (2003)
- Adler RA, "Clinical review 33: clinically important effects of alcohol on endocrine function", J Clin Endocrinol Metab, 74, pp.957~960 (1992)
- Malaga I, "Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy", Epilepsia, 47, pp.1576~1579 (2006)
- Hanavadi S, "The role of tamoxifen in the management of gynaecomastia", Breast, 15, pp.276~280 (2006)
- Bowman JD, "Drug-induced gynecomastia", Pharmacotherapy, 32, pp.1123~1140 (2012)
- McGrath MH, "Plastic surgery and the teenage patient", J Pediatr Adolesc Gynecol, 13, pp.105~118 (2000)
- Treves N, "Gynecomastia; the origins of mammary swelling in the male: an analysis of 406 patients with breast hypertrophy, 525 with testicular tumors, and 13 with adrenal neoplasms", Cancer, 11, pp.1083~1102 (1958)
- Jones DJ, "A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia:results of a prospective study in 55 patients", Ann R Coll Surg Engl, 72, pp.296~298 (1990)
- Mathur R, "Gynecomastia: pathomechanisms and treatment strategies", Horm Res Paediatr, 48, pp.95~102 (1997)
- Plourde PV, "Clomiphene in the treatment of adolescent gynecomastia. Clinical and endocrine studies", Am J Dis Child, 137, pp.1080~1082 (1983)
- Ting AC, "Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia", Am Surg, 66, pp.38~40 (2000)
- Zachmann M, "Treatment of pubertal gynaecomastia with testolactone", Eur J Endocrinol, (Suppl), pp.218~226 (1986)
- Miller WR, "The therapeutic potential of aromatase inhibitors", Expert Opin Investig Drugs, 12, pp.337~351 (2003)
- Riepe FG, "Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole", Horm Res Paediatr, 62, pp.113~118 (2004)